Camphoric Acid

Camphoric Acid

SCHEMBL52395

CC1(C)[C@@H](C(=O)O)CC[C@@]1(C)C(=O)O

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.66
LMNA P02545 2/20 0.57
POLB P06746 1/20 0.57
NPSR1 Q6W5P4 4/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
HTT P42858 1/20 0.47
TP53 P04637 1/20 0.47
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
CYP1A2 P05177 2/20 0.40
TSHR P16473 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2C9 P11712 1/20 0.40
FFAR3 O14843 1/20 0.37
GRM2 Q14416 2/20 0.35
GRM3 Q14832 2/20 0.35
GRM4 Q14833 2/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Camphoric Acid SCHEMBL12084182 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL2513165 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL30078310 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL23643 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL1738809 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL12308 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL7102028 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL12083956 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL7099871 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1
Camphoric Acid SCHEMBL27486599 1.00 ALDH1A1 (0.66) ALDH1A1LMNAPOLBNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630520-B2 Left-handed bicyclic morpholine and salt thereof, preparation method therefor, pharmaceutical composition, and use INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2026-05-19 US claimed
WO-2026086809-A1 PROCESS FOR PREPARING 3- [ (3AS, 6AR) -5- {5-CHLORO-2- [ (1-METHYL-1H-PYRAZOL-4-YL) AMINO] PYRIMIDIN-4-YL} -3A-METHYL-OCTAHYDROPYRROLO [3, 4-C] PYRROLE-2-YL] -3-OXOPROPIONITRILE BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) 2026-04-30 WO claimed
CN-120192277-A Preparation method of etomidate 仁合益康集团有限公司 2025-06-24 CN claimed
CN-116376043-B Cadmium metal-organic framework material with long afterglow characteristic and preparation method thereof 常州大学 2025-05-27 CN claimed
CN-119775545-A Water-soluble polyester resin, plasma etching protection liquid containing same, and preparation method and application thereof 深圳市化讯半导体材料有限公司 2025-04-08 CN claimed
CN-119771500-A Cobalt-based crystalline catalyst with three-dimensional porous structure, and preparation method and application thereof 上海应用技术大学 2025-04-08 CN claimed
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2025-03-27 US claimed
CN-116178746-B Cadmium metal-organic framework material with long afterglow characteristic, preparation method and application 常州大学 2025-03-18 CN claimed
CN-114660038-B Preparation method and application of chiral core-shell type nano probe 郑州大学 2024-12-03 CN claimed
CN-118947723-A Fosthiazate microcapsule suspending agent, preparation method and application 山东省绿士农药有限公司 2024-11-15 CN claimed
CN-111234505-A Environment-friendly damping rubber plate and preparation method thereof 谢强 2020-06-05 CN claimed
CN-111116655-A Preparation method of high-optical-purity tenofovir benzyl ester phosphonamide prodrug 天津天士力圣特制药有限公司 2020-05-08 CN claimed
CN-108997386-B Zinc metal organic complex constructed by double ligands and preparation method thereof 安徽理工大学 2020-05-08 CN claimed
WO-2018134836-A1 A NOVEL, FEASIBLE AND COST EFFECTIVE PROCESS FOR THE MANUFACTURE OF D – PENICILLAMINE SYNVEN SHREE LIFE SCIENCES PVT. LTD. (IN) 2018-07-26 WO claimed
US-8541095-B2 Security film and process for preparation thereof SHANGHAI TECHSUN ANTI-COUNTERFEITING TECHNOLOGY HOLDING CO., LTD. (CN) 2013-09-24 US claimed
EP-2329962-B1 SECURITY FILM AND PROCESS FOR PREPARATION THEREOF SHANGHAI TECHSUN ANTI COUNTERFEITING TECHNOLOGY HOLDING CO LTD (CN) 2012-09-05 EP claimed
US-20110293858-A1 SECURITY FILM AND PROCESS FOR PREPARATION THEREOF SHANGHAI FUDAN TECHSUN NEW TECHNOLOGY CO. LTD. (CN) 2011-12-01 US claimed
EP-2329962-A1 SECURITY FILM AND PROCESS FOR PREPARATION THEREOF Shanghai Fudan Techsun New Technology Co. Ltd. (CN) 2011-06-08 EP claimed
CN-101323229-A False proof thin film and preparation thereof SHANGHAI FUDAN TECHSUN NEW TEC (CN) 2008-12-17 CN claimed
US-4254053-A Process for manufacturing D camphorate of L carnitinamide and D camphorate of D carnitinamide Cavazza, Claudio (IT) 1981-03-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 ALDH1A1 1161/4885LMNA 1143/4885POLB 361/4885
US-12630520-B2 Left-handed bicyclic morpholine and salt thereof, preparation method therefor, pharmaceutical composition, and use GLS2, GOT1, MDH1 ALDH1A1 336/4885LMNA 3724/4885POLB 2038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.